Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections

Kohei Hara; Shigeru Kohno; Yasumasa Dohtsu; Kotaro Oizumi; Akira Watanabe; Kaoru Shimada; Hajime Goto; Masataka Katsu; Toshio Fukui; Setsuko Kurishima; Hiroyuki Kobayashi; Hisashi Inoue; Jingoro Shimada; Takaya Shiba; Masanobu Kaji; Hiroichi Tanimoto; Kazuo Ohara; Koichiro Nakata; Yoshitaka Nakamori; Junzaburo Kabe; Kohichiro Kudo; Isao Arioka; Shigeki Odagiri; Kaneo Suzuki; Kou Murohashi; Izumi Koyama; Osamu Sekine; Nobuki Aoki; Rinzo Soejima; Jiro Hino; Keizo Matsumoto; Toshiaki Yoshida; Naoto Rikitomi; Tsuyoshi Nagatake; Masakazu Takasugi; Masaru Nasu; Hideaki Shigeno; Jun Goto; Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Nobuya Ogawa; Keizo Yamaguchi; Kazuyuki Sugawara

doi:10.11250/chemotherapy1953.40.1057

Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections

Kohei Hara, Shigeru Kohno, Yasumasa Dohtsu, Kotaro Oizumi, Akira Watanabe, Kaoru Shimada, Hajime Goto, Masataka Katsu, Toshio Fukui, Setsuko Kurishima, Hiroyuki Kobayashi, Hisashi Inoue, Jingoro Shimada, Takaya Shiba, Masanobu Kaji, Hiroichi Tanimoto, Kazuo Ohara, Koichiro Nakata, Yoshitaka Nakamori, Junzaburo KabeKohichiro Kudo, Isao Arioka, Shigeki Odagiri, Kaneo Suzuki, Kou Murohashi, Izumi Koyama, Osamu Sekine, Nobuki Aoki, Rinzo Soejima, Jiro Hino, Keizo Matsumoto, Toshiaki Yoshida, Naoto Rikitomi, Tsuyoshi Nagatake, Masakazu Takasugi, Masaru Nasu, Hideaki Shigeno, Jun Goto, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Nobuya Ogawa, Keizo Yamaguchi, Kazuyuki Sugawara

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We carried out a dose finding comparative study using ceftazidime (CAZ) as a reference drug to determine the optimal dose of cefclidin (CFCL), a newer parenteral cephalosporin, in the treatment of chronic respiratory tract infections. As a rule CFCL was injected in a total dose of 2 g a day (1 g twice a day) or 4 g a day (2 g twice a day), and CAZ was injected in a total dose of 2 g a day (1 g twice a day) for 14 days. A total of 136 patients (CFCL 2 g group: 45 patients; CFCL 4 g group: 44 patients; CAZ group: 47 patients) were enrolled. Clinical efficacy and safety assessments were made in 124 patients (CFCL 2 g group: 39 patients; CFCL 4 g group: 41 patients; CAZ group: 44 patients) and 129 patients (CFCL 2 g group: 41 patients, CFCL 4 g group: 43 patients; CAZ group: 45 cases). These findings indicate that CFCL 2 g a day (1 g twice a day) and CFCL 4 g a day (2 g twice a day) are almost the same from the standpoint of overall clinical efficacy and safety. Based on these results, we concluded that CFCL 2 g a day was the optimal dosage in the treatment of chronic respiratory tract infections, including a P. aeruginosa infection, from the point of view of efficacy and safety.

Original language	English
Pages (from-to)	1057-1076
Number of pages	20
Journal	Chemotherapy
Volume	40
Issue number	8
DOIs	https://doi.org/10.11250/chemotherapy1953.40.1057
Publication status	Published - 1992 Aug
Externally published	Yes

Keywords

CAZ
Dose finding study
Respiratory tract infections (RTI)
cefclidin (CFCL, E 1040)

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.1057

Cite this

Hara, K., Kohno, S., Dohtsu, Y., Oizumi, K., Watanabe, A., Shimada, K., Goto, H., Katsu, M., Fukui, T., Kurishima, S., Kobayashi, H., Inoue, H., Shimada, J., Shiba, T., Kaji, M., Tanimoto, H., Ohara, K., Nakata, K., Nakamori, Y., ... Sugawara, K. (1992). Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections. Chemotherapy, 40(8), 1057-1076. https://doi.org/10.11250/chemotherapy1953.40.1057

Hara, K, Kohno, S, Dohtsu, Y, Oizumi, K, Watanabe, A, Shimada, K, Goto, H, Katsu, M, Fukui, T, Kurishima, S, Kobayashi, H, Inoue, H, Shimada, J, Shiba, T, Kaji, M, Tanimoto, H, Ohara, K, Nakata, K, Nakamori, Y, Kabe, J, Kudo, K, Arioka, I, Odagiri, S, Suzuki, K, Murohashi, K, Koyama, I, Sekine, O, Aoki, N, Soejima, R, Hino, J, Matsumoto, K, Yoshida, T, Rikitomi, N, Nagatake, T, Takasugi, M, Nasu, M, Shigeno, H, Goto, J, Saito, A, Shigeno, Y, Irabu, Y, Ogawa, N, Yamaguchi, K & Sugawara, K 1992, 'Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections', Chemotherapy, vol. 40, no. 8, pp. 1057-1076. https://doi.org/10.11250/chemotherapy1953.40.1057

@article{a4920be40b38440b8acdb9f843c01645,

title = "Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections",

abstract = "We carried out a dose finding comparative study using ceftazidime (CAZ) as a reference drug to determine the optimal dose of cefclidin (CFCL), a newer parenteral cephalosporin, in the treatment of chronic respiratory tract infections. As a rule CFCL was injected in a total dose of 2 g a day (1 g twice a day) or 4 g a day (2 g twice a day), and CAZ was injected in a total dose of 2 g a day (1 g twice a day) for 14 days. A total of 136 patients (CFCL 2 g group: 45 patients; CFCL 4 g group: 44 patients; CAZ group: 47 patients) were enrolled. Clinical efficacy and safety assessments were made in 124 patients (CFCL 2 g group: 39 patients; CFCL 4 g group: 41 patients; CAZ group: 44 patients) and 129 patients (CFCL 2 g group: 41 patients, CFCL 4 g group: 43 patients; CAZ group: 45 cases). These findings indicate that CFCL 2 g a day (1 g twice a day) and CFCL 4 g a day (2 g twice a day) are almost the same from the standpoint of overall clinical efficacy and safety. Based on these results, we concluded that CFCL 2 g a day was the optimal dosage in the treatment of chronic respiratory tract infections, including a P. aeruginosa infection, from the point of view of efficacy and safety.",

keywords = "CAZ, Dose finding study, Respiratory tract infections (RTI), cefclidin (CFCL, E 1040)",

author = "Kohei Hara and Shigeru Kohno and Yasumasa Dohtsu and Kotaro Oizumi and Akira Watanabe and Kaoru Shimada and Hajime Goto and Masataka Katsu and Toshio Fukui and Setsuko Kurishima and Hiroyuki Kobayashi and Hisashi Inoue and Jingoro Shimada and Takaya Shiba and Masanobu Kaji and Hiroichi Tanimoto and Kazuo Ohara and Koichiro Nakata and Yoshitaka Nakamori and Junzaburo Kabe and Kohichiro Kudo and Isao Arioka and Shigeki Odagiri and Kaneo Suzuki and Kou Murohashi and Izumi Koyama and Osamu Sekine and Nobuki Aoki and Rinzo Soejima and Jiro Hino and Keizo Matsumoto and Toshiaki Yoshida and Naoto Rikitomi and Tsuyoshi Nagatake and Masakazu Takasugi and Masaru Nasu and Hideaki Shigeno and Jun Goto and Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Nobuya Ogawa and Keizo Yamaguchi and Kazuyuki Sugawara",

year = "1992",

month = aug,

doi = "10.11250/chemotherapy1953.40.1057",

language = "English",

volume = "40",

pages = "1057--1076",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "8",

}

TY - JOUR

T1 - Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Dohtsu, Yasumasa

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Shimada, Kaoru

AU - Goto, Hajime

AU - Katsu, Masataka

AU - Fukui, Toshio

AU - Kurishima, Setsuko

AU - Kobayashi, Hiroyuki

AU - Inoue, Hisashi

AU - Shimada, Jingoro

AU - Shiba, Takaya

AU - Kaji, Masanobu

AU - Tanimoto, Hiroichi

AU - Ohara, Kazuo

AU - Nakata, Koichiro

AU - Nakamori, Yoshitaka

AU - Kabe, Junzaburo

AU - Kudo, Kohichiro

AU - Arioka, Isao

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Murohashi, Kou

AU - Koyama, Izumi

AU - Sekine, Osamu

AU - Aoki, Nobuki

AU - Soejima, Rinzo

AU - Hino, Jiro

AU - Matsumoto, Keizo

AU - Yoshida, Toshiaki

AU - Rikitomi, Naoto

AU - Nagatake, Tsuyoshi

AU - Takasugi, Masakazu

AU - Nasu, Masaru

AU - Shigeno, Hideaki

AU - Goto, Jun

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Ogawa, Nobuya

AU - Yamaguchi, Keizo

AU - Sugawara, Kazuyuki

PY - 1992/8

Y1 - 1992/8

N2 - We carried out a dose finding comparative study using ceftazidime (CAZ) as a reference drug to determine the optimal dose of cefclidin (CFCL), a newer parenteral cephalosporin, in the treatment of chronic respiratory tract infections. As a rule CFCL was injected in a total dose of 2 g a day (1 g twice a day) or 4 g a day (2 g twice a day), and CAZ was injected in a total dose of 2 g a day (1 g twice a day) for 14 days. A total of 136 patients (CFCL 2 g group: 45 patients; CFCL 4 g group: 44 patients; CAZ group: 47 patients) were enrolled. Clinical efficacy and safety assessments were made in 124 patients (CFCL 2 g group: 39 patients; CFCL 4 g group: 41 patients; CAZ group: 44 patients) and 129 patients (CFCL 2 g group: 41 patients, CFCL 4 g group: 43 patients; CAZ group: 45 cases). These findings indicate that CFCL 2 g a day (1 g twice a day) and CFCL 4 g a day (2 g twice a day) are almost the same from the standpoint of overall clinical efficacy and safety. Based on these results, we concluded that CFCL 2 g a day was the optimal dosage in the treatment of chronic respiratory tract infections, including a P. aeruginosa infection, from the point of view of efficacy and safety.

AB - We carried out a dose finding comparative study using ceftazidime (CAZ) as a reference drug to determine the optimal dose of cefclidin (CFCL), a newer parenteral cephalosporin, in the treatment of chronic respiratory tract infections. As a rule CFCL was injected in a total dose of 2 g a day (1 g twice a day) or 4 g a day (2 g twice a day), and CAZ was injected in a total dose of 2 g a day (1 g twice a day) for 14 days. A total of 136 patients (CFCL 2 g group: 45 patients; CFCL 4 g group: 44 patients; CAZ group: 47 patients) were enrolled. Clinical efficacy and safety assessments were made in 124 patients (CFCL 2 g group: 39 patients; CFCL 4 g group: 41 patients; CAZ group: 44 patients) and 129 patients (CFCL 2 g group: 41 patients, CFCL 4 g group: 43 patients; CAZ group: 45 cases). These findings indicate that CFCL 2 g a day (1 g twice a day) and CFCL 4 g a day (2 g twice a day) are almost the same from the standpoint of overall clinical efficacy and safety. Based on these results, we concluded that CFCL 2 g a day was the optimal dosage in the treatment of chronic respiratory tract infections, including a P. aeruginosa infection, from the point of view of efficacy and safety.

KW - CAZ

KW - Dose finding study

KW - Respiratory tract infections (RTI)

KW - cefclidin (CFCL, E 1040)

UR - http://www.scopus.com/inward/record.url?scp=0026754498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026754498&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.1057

DO - 10.11250/chemotherapy1953.40.1057

M3 - Article

AN - SCOPUS:0026754498

SN - 0009-3165

VL - 40

SP - 1057

EP - 1076

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 8

ER -

Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this